

3-Ethylsulfonyl-2-phenylquinoxaline 1,4-dioxide

Fa-Qin Jiang and Yong-Zhou Hu*

Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, Hangzhou 310031, People's Republic of China

Correspondence e-mail: huyz@zjuem.zju.edu.cn

Key indicators

Single-crystal X-ray study

 $T = 298\text{ K}$ Mean $\sigma(\text{C}-\text{C}) = 0.002\text{ \AA}$ R factor = 0.041 wR factor = 0.110

Data-to-parameter ratio = 16.8

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


In the title compound, $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_4\text{S}$, the phenyl and quinoxaline 1,4-dioxide planes are approximately perpendicular, with a dihedral angle of $85.8(2)^\circ$.

Received 4 January 2006

Accepted 13 January 2006

Comment

Quinoxaline 1,4-dioxides have become an attractive target for organic chemists because of their broad range of biological activities, such as antibacterial (Takabatake *et al.*, 1996), antitubercular (Jaso *et al.*, 2005), cytotoxic (Torre *et al.*, 2005), herbicidal (Ma *et al.*, 2004) and antimalarial (Aldana *et al.*, 2003) activities. In order to study their cytotoxic activity, a series of 2-substituted-phenyl-3-ethylsulfonylquinoxaline 1,4-dioxide has been synthesized. As part of the study, the structure of the title compound, (I), has been determined, and we present the results here.



In (I), the quinoxaline 1,4-dioxide system is almost planar (Fig. 1 and Table 1). The quinoxaline 1,4-dioxide and phenyl planes are approximately perpendicular, with a dihedral angle of $85.8(2)^\circ$.

Experimental

2-Ethylthioacetophenone (10 mmol) and benzofuroxan (10 mmol) were dissolved in methanol (100 ml) and ammonia gas was bubbled in for 10 min. The reaction mixture was then allowed to stand at room temperature overnight. The crystalline precipitate which formed was filtered off and washed with methanol to give 2-phenyl-3-ethylthioquinoxaline 1,4-dioxide. A solution of *m*-chloroperbenzoic acid (10 mmol) in chloroform (30 ml) was added dropwise to an ice-cold solution of 2-phenyl-3-ethylthioquinoxaline 1,4-dioxide (5 mmol) in chloroform (15 ml), and the reaction mixture was stirred at room temperature overnight. The chloroform solution was washed with aqueous sodium bicarbonate, dried over magnesium sulfate and filtered. After removing the solvent in a vacuum, the residue was purified by crystallization from methanol–chloroform (10:1 *v/v*) to

afford the title compound, (I). Crystals of (I) suitable for X-ray diffraction were obtained by slow evaporation of an ethanol–chloroform solution (25:1 v/v) of the compound at room temperature.

Crystal data

C₁₆H₁₄N₂O₄S
M_r = 330.36
 Monoclinic, *P*2₁/*n*
a = 10.261 (5) Å
b = 8.573 (4) Å
c = 17.898 (7) Å
 β = 104.415 (16)°
V = 1524.9 (11) Å³
Z = 4

D_x = 1.439 Mg m⁻³
 Mo *K*α radiation
 Cell parameters from 11903 reflections
 θ = 3.1–27.5°
 μ = 0.23 mm⁻¹
T = 298 (1) K
 Prism, brown
 0.55 × 0.45 × 0.32 mm

Data collection

Rigaku R-AXIS RAPID diffractometer
 ω scans
 Absorption correction: multi-scan (ABSCOR; Higashi, 1995)
T_{min} = 0.859, *T_{max}* = 0.928
 14375 measured reflections

3489 independent reflections
 2423 reflections with *F*² > 2σ(*F*²)
R_{int} = 0.026
 θ_{max} = 27.5°
h = -13 → 13
k = -11 → 8
l = -23 → 23

Refinement

Refinement on *F*²
R[*F*² > 2σ(*F*²)] = 0.041
wR(*F*²) = 0.110
S = 1.01
 3489 reflections
 208 parameters

H-atom parameters constrained
w = 1/[0.0009*F_o*² + σ(*F_o*²)]/(4*F_o*²)
 (Δ/σ)_{max} < 0.001
 Δρ_{max} = 0.29 e Å⁻³
 Δρ_{min} = -0.29 e Å⁻³

Table 1

Selected geometric parameters (Å, °).

S1–O3	1.4245 (15)	S1–C15	1.764 (2)
S1–O4	1.4169 (13)	O1–N1	1.277 (2)
S1–C1	1.8054 (17)	O2–N2	1.2811 (19)
O1–N1–C2–C3	2.8 (2)	N2–C8–C9–C10	-92.2 (2)
O2–N2–C7–C6	-3.7 (2)		

All H atoms were placed in geometrically idealized positions. The methyl H atoms were then constrained to an ideal geometry, with C–H = 0.96 Å and *U*_{iso}(H) = 1.2*U*_{eq}(C), but the group was allowed to rotate freely about its C–C bond. Other H atoms were constrained to ride on their parent atoms, with C–H = 0.93–0.97 Å and *U*_{iso}(H) = 1.2*U*_{eq}(C).

Data collection: *PROCESS-AUTO* (Rigaku, 1998); cell refinement: *PROCESS-AUTO*; data reduction: *CrystalStructure* (Rigaku/MSK, 2004); program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *CRYSTALS* (Betteridge *et al.*, 1996); molecular graphics: *ORTEP-3 for Windows*




Figure 1

The molecular structure of (I), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 40% probability level.

(Farrugia, 1997); software used to prepare material for publication: *CrystalStructure*.

The authors are grateful to Mr Jianmin Gu of the analysis center of Zhejiang University for helpful assistance.

References

Aldana, I., Ortega, M. A., Jaso, A., Zarranz, B., Oporto, P., Gimenez, A., Monge, A. & Deharo, E. (2003). *Pharmazie*, **58**, 68–69.
 Altomare, A., Burla, M. C., Camalli, M., Cascarano, G., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). *J. Appl. Cryst.* **32**, 115–119.
 Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin, D. J. (2003). *J. Appl. Cryst.* **36**, 1487.
 Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
 Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
 Jaso, A., Zarranz, B., Aldana, I. & Monge, A. (2005). *J. Med. Chem.* **48**, 2019–2025.
 Ma, J.-Zh., Wang, H.-B. & Jiang, H. (2004). *Jingxi Huagong*, **21**, 309–312. (In Chinese.)
 Rigaku (1998). *PROCESS-AUTO*. Version 1.06. Rigaku Corporation, Tokyo, Japan.
 Rigaku/MSK (2004). *CrystalStructure*. Version 3.7.0. Rigaku/MSK, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
 Takabatake, T., Takabatake, Y., Miyazawa, T. & Hasegawa, M. (1996). *Yakugaku Zasshi*, **116**, 491–496. (In Japanese.)
 Torre, M. H., Gambino, D., Araujo, J., Cerecetto, H., Gonzalez, M., Lavaggi, M. L., Azqueta, A., Lopez de Cerain, A., Vega, A. M., Abram, U. & Costa-Filho, A. J. (2005). *Eur. J. Med. Chem.* **40**, 473–480.